People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

“Spravato is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days, without the need for daily oral ...

“Spravato ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily ...

Spravato (esketamine) was approved by the EMA in December as an adjunctive, add-on therapy for people with serious depression who don’t respond to treatment with at least two from the current ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...